Skip to content

Moderna, Inc.

MRNA· Nasdaqxbrl foundCIK 1682852

Biological products, except diagnostic substances175 peers

Last sale
Nov 12, 2026 · -6.97%
Market cap
$93.61B
404.62M shares
Filings
1,053
$1.31B
Q3 2026−39.9% FY25 yoy
$162.00M
Q3 2026N/M FY25 yoy
$130.00M
Q3 2026N/M FY25 yoy
-$2.86B
Q3 2026derivedN/M FY25 yoy
$0.38
Q3 2026N/M FY25 yoy
$1.20B
Q3 2026+34.7% FY25 yoy
$93.61B
—
37.1×
13.7×
-2.10%
—

Twelve months to Sep 30, 2026 · derived

Price

$231.35+775.33%+$204.92past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$1.94BFY 2025
$19.26B0FY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$1,944,000,000reported
FY 20242024-12-31$3,236,000,000reported
FY 20232023-12-31$6,848,000,000reported
FY 20222022-12-31$19,263,000,000reported
FY 20212021-12-31$18,471,000,000reported
FY 20202020-12-31$803,000,000reported
FY 20192019-12-31$60,209,000 revisedreported
FY 20182018-12-31$135,068,000reported
FY 20172017-12-31$205,825,000reported
FY 20162016-12-31$108,396,000reported

Capital returns

Dividends and buybacks · FY2019 to FY2025
Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2025—$2.00M$2.00M—394.94M sh+2.4%—
FY2024—$0.00$0.00—385.82M sh+1.0%—
FY2023—$1.15B$1.15B—382.07M sh−1.1%—
FY2022—$3.33B$3.33B—386.34M sh−4.1%72.7%
FY2021—$857.00M$857.00M—402.87M sh+0.8%6.4%

Segments

Revenue by Geography, FY2018 to FY2022FY2018United States · FY2018 · $89.08MRest of world · FY2018 · $45.99MFY2019Europe · FY2019 · $5.00MUnited States · FY2019 · $55.00MRest of world · FY2019 · $5.23MFY2020Rest of world · FY2020 · $6.00MEurope · FY2020 · $33.00MUnited States · FY2020 · $764.00MRest of world · FY2020 · $38.87MFY2021Rest of world · FY2021 · $5.45BEurope · FY2021 · $6.85BUnited States · FY2021 · $6.18BFY2022Rest of world · FY2022 · $7.30BEurope · FY2022 · $6.82BUnited States · FY2022 · $5.15B
LineFY2022ShareChange
Rest of world$7.30B38%+34.0%
Europe$6.82B35%−0.5%
United States$5.15B27%−16.6%
Rest of world———
Total$19.26B

From the 10-K filed Feb 24, 2023MRNA

Biological products, except diagnostic substances

Moderna, Inc. is the 7th largest of the 176 covered companies the SEC files under this code, by revenue. SIC 2836

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Moderna, Inc. · CIK 1682852 · Engraved from SEC EDGAR